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New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), continue to rise worldwide following the declaration of a pandemic by the World
Health Organization (WHO). The current pandemic has completely altered the workflow of health services
worldwide. However, even during this critical period, patients with other diseases, like cancer, need to be
properly treated.
A few reports have shown that mortality due to SARS-CoV-2 is higher in elderly patients and those with other
active comorbidities, including cancer. Patients with lung cancer are at risk of pulmonary complications from
COVID-19, and as such, the risk/benefit ratio of local and systemic anticancer treatment has to be considered. For
each patient, several factors, including age, comorbidities, and immunosuppression, as well as the number of
hospital visits for treatment, can influence this risk. The number of cases is rising exponentially in Brazil, and it is
important to consider the local characteristics when approaching the pandemic. In this regard, the Brazilian
Thoracic Oncology Group has developed recommendations to guide decisions in lung cancer treatment during
the SARS-CoV-2 pandemic. Due to the scarcity of relevant data, discussions based on disease stage, evaluation of
surgical treatment, radiotherapy techniques, systemic therapy, follow-up, and supportive care were carried out,
and specific suggestions issued. All recommendations seek to reduce contagion risk by decreasing the number
of medical visits and hospitalization, and in the case of immunosuppression, by adapting treatment schemes
when possible. This statement should be adjusted according to the reality of each service, and can be revised as
new data become available.
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’ INTRODUCTION
On December 31, 2019, the World Health Organization
(WHO) was informed of a high incidence of pneumonia
cases in the city of Wuhan, Hubei Province of China.
On January 7, 2020, Chinese authorities confirmed the
pneumonia outbreak was caused by a new type of virus,
which belongs to a family known as Coronaviruses (1). Some
of the viruses in the Coronaviruses family already exist in
Brazil, and are capable of causing a common cold; however,
the coronavirus family also encompasses viruses like SARS
and MERS that caused epidemics with a large number of
deaths in 2004 and 2012, respectively. The new virus is
believed to have been transmitted from another species of
animal, bats are currently suspected, to humans (2). On
February 26, 2020, the first case of this disease was reported
in Brazil, a 61-year-old man who had recently been abroad.
Since then, the number of cases grew rapidly, and in early
May, the virus death toll in Brazil was over 10,000, with over
600 deaths reported per day (3).
The coronavirus disease 2019 (COVID-19) is the disease
caused by the newly identified virus, of the CoronavirusesDOI: 10.6061/clinics/2020/e2060
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family - severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). COVID-19 has evolved rapidly, and based on
the increase in the number of cases and fast global spread,
the WHO classified the outbreak as a pandemic on March 11,
2020. The COVID-19 pandemic is now one of the world’s
most serious public health problems in recent years. This
being the case, all health organizations had to drastically
rearrange their activities to face the challenges posed by this
new disease. These changes are even more challenging when
they involve patients with chronic diseases, including cancer.
In particular, in the case of patients with suspected or
diagnosed lung cancer, there are peculiarities that must be
addressed within the context of the current pandemic.
Clinical findings and imaging in the early stages of
COVID-19 pneumonia may resemble common findings in
patients with lung cancer, like treatment complications
(caused by immunotherapy, chemotherapy, radiotherapy,
and/or targeted therapies) and other infectious complica-
tions (4). Furthermore, patients with suspected or diagnosed
lung cancer often undergo invasive thoracic procedures,
which increases their risk of complications in case of a SARS-
CoV-2 infection. It is important to mention that most are
patients with advanced lung cancer for whom decisions
regarding non-invasive, psychological and familiar support,
and comfort care measures have a critical role.
For these reasons, the Brazilian Thoracic Oncology Group
(GBOT) have outlined guidelines that are both consensus-
based, representing major cancer treatment medical societies,
and localized, taking into account local needs for managing
these patients. These guidelines will be updated as and when
new relevant information becomes available.
’ LUNG CANCER AS A RISK FACTOR FOR COVID-19
Although any individual can be infected by COVID-19,
certain populations are more likely to develop complications
and severe forms of the disease. Based on previous studies,
patients over 65 years of age, living in nursing homes, and
suffering from comorbidities, including chronic lung dis-
eases, moderate to severe asthma, heart diseases, immuno-
suppression conditions, severe obesity (a BMI of 40 or
higher), diabetes mellitus, chronic kidney disease on dialysis,
and liver disease (5) are more likely to develop severe
disease. Consequently, there are greater chances of lung
cancer patients falling into a high-risk group. Although all
types of neoplasia appear to be associated with high
prevalence, morbidity, and mortality from COVID-19, lung
cancer represents a specific situation involving cumulative
risk factors for COVID-19 complications, including advanced
age, significant cardiovascular and respiratory comorbidities,
lung damage caused by smoking, impairment of immune
function following cancer treatment (or cancer itself), or the
frequent use of corticosteroids.
Numerous studies on COVID-19 in cancer patients have
confirmed this scenario. Among 1,524 cancer patients admit-
ted to the Department of Radiation and Medical Oncology at
Zhongnan Hospital of Wuhan University in Wuhan, China,
0.79% had COVID-19 versus 0.37% of the general population
of Wuhan over the same study period (OR, 2.31; 95% CI,
1.89–3.02). In the same study, patients with non-small cell
lung cancer (NSCLC) seemed to have a higher incidence
of COVID-19, especially those over 60 years of age (4.3%
versus 1.8% in those aged under 60 years with NSCLC) (6).
According to another retrospective case study published by a
Chinese team, cancer patients (most frequently, advanced lung
cancer [28%]) were at higher risk of severe complications and
unfavorable outcomes than hospitalized cancer-free patients
(7). This same finding was also reported in at least two
other analyses. Smoking history also seems to increase the
risk of complications by up to 1.4-fold, and by 2.4-fold that
of death or need for mechanical ventilation due to COVID-
19 (8,9).
During a recent plenary session of the American Associa-
tion for Cancer Research annual congress on ‘‘COVID-19 and
Cancer,’’ an international team led by Dr. Marina Garassino
presented initial data from TERAVOLT (Thoracic cancERs
internAtional coVid 19 cOLlaboraTion) a global registry
gathering information on patients with thoracic cancers
infected with COVID-19 – in which a 34.6% mortality rate
(66/191) among patients with thoracic cancer was repor-
ted. In addition, the most common complications were
pneumonia and pneumonitis (79.6%; 125/157), acute
respiratory distress syndrome (26.8%; 42/157), multiple
organ failure (7.6%; 12/157), and sepsis in (5.1%; 8/157).
The cause of death in most of these patients was attributed
to COVID-19 and not to cancer itself (10). For these reasons,
lung cancer patients must be considered to be at greater risk of
developing COVID-19 complications, regardless of the cancer
staging.
’ RECOMMENDATION OF LUNG CANCER
MANAGEMENT ACCORDING TO DISEASE STAGE
Decisions about procedures, work-up, and treatment must
be tailored by factors like disease stage, molecular and
histology diagnosis, patient clinical status, local infrastruc-
ture, and pandemic characteristics. In this regard, the
following recommendations were adopted by the American
College of Surgeons classification of phased units, based
on disease burden and available facilities and resources
(Table 1) (11).
MANAGEMENT DURING DIAGNOSIS AND STAGING
Given the high aggressiveness and mortality of lung
cancer, decisions to postpone diagnostic procedures must
be evaluated very carefully on a case-by-case basis, and
patient and family expectations should be considered in the
decision. The risks of medical visits and procedures can vary,
and depend on social isolation, exposition to contamina-
ted patients or health staff in outpatient and inpatient
units, invasive procedures to the airways and thorax,
hospitalization, and immunosuppression. In all situations,
it is recommended to closely observe the current status and
changes in the scenario of individual institutions in the face
of the pandemic. Whenever possible, patients should be
Table 1 - Facilities classification for elective case triage for cancer
care.
Phase Facility and epidemiogical characteristics
Phase 1 Few COVID-19 patients, hospital resources not exhausted,
institution still has ICU vent capacity, and COVID trajectory
not in rapid escalation phase
Phase 2 Many COVID-19 patients, ICU and ventilator capacity
limited, OR supplies limited, or COVID trajectory within
hospital in rapidly escalating phase
Phase 3 Hospital resources are all routed to COVID-19 patients,
no ventilator or ICU capacity, OR supplies exhausted
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transported to Phase 1 units and the following measures
evaluated:
1. Limit the number of invasive procedures and hospitaliza-
tions when there is no harm to the conduction of the
case. For instance, mediastinoscopy and surgery could be
performed at the same time, and diagnostic biopsies could
be omitted in highly suspicious lesions before surgery.
2. Avoid procedures with airway manipulation, such as
diagnostic bronchoscopy, endoscopic bronchoscopy (EBUS)
for diagnosis and staging, echoendoscopy, and pulmonary
function tests (spirometry).
3. Prefer percutaneous procedures for diagnosis and staging,
performed in an outpatient or day hospital facility.
4. Perform PET-Computed Tomography (CT) scan only
when it can potentially modify staging. For instance,
multiple imaging exams could be avoided in patients
already diagnosed with stage IV disease.
5. Concentrate staging exams on the same day.
6. Option for imaging follow-up is possible in cases of low or
intermediate risk: a) lesions with predominant ground glass
opacities (o50% solid area); b) solid nodule smaller than
2 cm; c) pleural-based solid nodule o5 mm; d) benign
morphology; f) known volume doubling time 4600 days
(11);
7. Lung cancer screening should be deferred until the
COVID-19 pandemic resolves (12).
INITIAL DISEASE MANAGEMENT
There is still paucity of data addressing initial lung cancer
during COVID-19. In this subgroup, age was an important
risk factor for complications, and the treatment complication
rates appear to be higher in patients with advanced disease.
Therefore, when approaching a patient with initial disease,
we must consider age, the presence of other comorbidities,
contagion risk, potential treatment-related or primary immu-
nosuppression, use of ventilation equipment, and intensive
care unit (ICU) beds. In this sense, we recommend, whenever
possible, to transfer the patient to Phase 1 units and evaluate
the following measures:
1. Discuss stereotactic ablative radiotherapy (SABR) in
patients with stage I and II disease, especially if X70
years of age and at higher surgical risk.
2. Prefer hypofractionated radiation therapy when possible.
For peripheral located lesions, treatment may be per-
formed over 1–3 fractions, for central located lesions in
five fractions, and for ultra-central located lesions in eight
fractions.
3. Avoid open surgeries (thoracotomy) or any procedure
that could increase the postoperative period and com-
plications.
4. Minimally invasive techniques are highly recommended,
like video assisted (VATS) or robotic video assisted tech-
niques (R-VATS). During the surgical approach, CO2
insufflation is possible, avoiding gas leakage through the
portals, and taking extra care at the end of the procedure,
before removing the surgical specimen, to filter gas from
the cavity through antiviral filters. Bipolar energy instru-
ments are recommended, to reduce smoke formation and
aerosolization. Connect an antiviral filter or other suitable
device to the drainage system, especially if there is an
air leak.
5. Use of personal protective equipment (PPE) by authorized
professionals during the surgical procedure.
6. Perform chest CT scan 24–48 hours before surgery, to
assess the presence of suspected lesions for COVID-19
(recommended).
7. Collect nasal swab to perform PCR to test for SARS-CoV-2
before the procedure (recommended).
8. Surgical approaches that should not be delayed at this
time, unless only Phase 3 units are available:
a Solid or predominantly solid lesions (450%) in patients
with NSCLC with negative lymph nodes.
b Suspected lesions for lung cancer larger than 2.0 cm
with negative lymph nodes.
c Mediastinoscopy or surgical procedures for staging; for
example, videothoracoscopy to assess pleural effusion.
9. Surgical approaches that may be postponed:
a Indolent histologies (carcinoid tumor, lepidic adenocar-
cinoma, with pure ground glass opacity).
b Resectable small cell lung cancer (SCLC) patients - start
with neoadjuvant chemotherapy.
10. Do not indicate adjuvant chemotherapy in CPNPC stage
oIB (T2aN0).
11. In candidates for perioperative chemotherapy (CT),
prefer neoadjuvant chemotherapy (recommended schemes
with less risk of hospitalization and number of visits to the
treatment center: Non-squamous histology, Cisplatin/
Pemetrexed; squamous histology: cisplatin/docetaxel).
12. Use granulocyte colony-stimulating factor (G-CSF) as
primary prophylaxis to reduce risk of hospitalization
during neoadjuvant or adjuvant CT if risk of febrile
neutropenia is X10%.
13. Consider adjuvant treatment with gefitinib 250 mg
VO for 2 years, for elderly operated patients with a
sensitivity EGFR mutation (exon 19 deletion or L858R
exon 21 mutation) who have indication of adjuvant CT
and higher risk of COVID-19 complications.
14. Prophylactic cranial irradiation for SCLC should be
discussed, and may be postponed for up to 2–3 months.
LOCALLY ADVANCED DISEASE MANAGEMENT
Patients with locally advanced disease may present
in different stages and situations, and decisions should be
made on a case-by-case basis. All previous recommenda-
tions regarding surgical and staging procedures should be
followed. Since locally advanced lung cancer is a high-risk
disease, as a general rule, treatments should not be post-
poned, but adapted whenever possible, to deal with
challenges brought by the pandemic. We must take into
account the presence of other comorbidities, age, perfor-
mance status (PS), and treatment-related or primary immu-
nosuppression, and try to reduce the contagion risk, number
of visits to the treatment center, hospitalizations, use of ven-
tilation equipment, and ICU beds. We recommend, when-
ever possible, to transfer patients to Phase 1 hospitals and
evaluate the following measures:
1. Keep multidisciplinary decisions through web-based tumor
boards.
2. For candidates of perioperative CT, prefer a neoadjuvant
approach (recommended schemes with less risk of hospi-
talization and number of visits to the treatment center:
3
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Non-squamous histology, cisplatin/pemetrexed; squa-
mous histology: cisplatin/docetaxel).
3. Candidates with concomitant CTand radiotherapy should
not have treatment suspended or postponed. Instead,
CT schemes with less infusion days and less risk of
hospitalization or immunosuppression should be consid-
ered. Radiotherapy should be started on the first day of
CT infusion (to avoid more CT cycles). Furthermore, the
standard RT dosage for locally advanced disease is 60 Gy
in 30 fractions, but hypofractionated schemes can be
adopted, respecting equivalent efficacy dosage and dose-
volume predictors and constraints for toxicity.
4. Immunotherapy maintenance with durvalumab can be
prescribed, and an adapted schedule might be considered
(durvalumab 1500 mg IV every 4 weeks). This recom-
mendation is not available as drug package insert, but we
consider that there is sufficient security and efficacy data
published (13).
5. Adjuvant radiotherapy for pathologic stage N2 disease
(pN2) should be individualized.
6. Adjuvant radiotherapy for N0 disease post neoadjuvant
treatment (ypN0) should not be recommended.
7. Prophylactic cranial irradiation for SCLC should be
discussed, and may be postponed for up to 2–3 months.
8. Consolidation thoracic irradiation for SCLC should not be
routinely indicated.
9. Use G-CS as primary prophylaxis, to the reduce risk of
hospitalization during CT if risk of febrile neutropenia
X10%.
ADVANCED DISEASE MANAGEMENT
Although patients with advanced disease are at greater
risk of complications from COVID-19, due to the severity of
the neoplasia, treatments should generally not be postponed.
We must consider the presence of other comorbidities,
age, and PS, and try to reduce contagion risk, decrease
the hospitalizations and the number of visits to the treatment
center, reduce immunosuppression, and reduce use of equip-
ment and ICU beds in hospitals. We recommend, whenever
possible, to transfer patients to Phase 1 hospitals and
evaluate the following measures (12):
1. Prefer to start targeted therapy over CT/immunotherapy
(IO), whenever possible. In patients already undergoing
CT with partial response, a change to targeted therapy
should be considered.
2. For patients with high PD-L1 expression (X50%): con-
sider using IO as monotherapy, with adapted dosage
(pembrolizumab 400 mg IV every 6 weeks).
3. For patients undergoing IO, adapt the dosage (Nivolumab
480 mg IV every 4 weeks; Pembrolizumab 400 mg IV
every 6 weeks).
4. For patients undergoing maintenance CT (pemetrexed)
and IO, consider pemetrexed suspension and mainte-
nance of IO alone with an adapted dosage (pembrolizu-
mab 400 mg IV every 6 weeks).
5. Avoid prescribing a third or fourth line of chemotherapy
in patients with comorbidities.
6. Use G-CSF as primary prophylaxis to reduce the risk of
hospitalization during CT, if the risk of febrile neutropenia
is X10%.
7. Adopt home administration for subcutaneous medica-
tions if feasible.
8. Postpone infusion of bisphosphonates (acid zolendronic
every 3 months).
9. Prefer darbepoetin alfa 500 mg SC every 3 weeks for
the treatment of anemia secondary to CT. Avoid blood
transfusions.
10. When possible, postpone local treatment of oligometas-
tasis. Prefer SABR and avoid surgical procedures in these
cases.
11. Brain metastases: prefer radiotherapy to surgery, and
hypofractionated radiotherapy when possible. Avoid
radiation therapy or surgery if effective targeted therapy
is available and the disease is oligo- or asymptomatic.
12. Prophylactic CNS radiotherapy for SCLC should not
be indicated. Consider follow-up with brain magnetic
resonance imaging (MRI).
ADVANCED DISEASE - PALLIATIVE
CARE MANAGEMENT
Patients with advanced lung cancer in palliative care are
a major challenge in the face of the COVID-19 pandemic.
In this scenario, we must reduce contagion risk and family
exposure, promote social isolation, try to reduce the use
of ventilation equipment and ICU beds in hospitals, and
provide psychological support to patients and their family.
Whenever possible, we recommend transferring the patient
to Phase 1 hospitals and implementing the following
measures:
1. Discuss, for patients in exclusive palliative care, living
wills and advance directives for medical decisions.
2. Define in medical records the level of support that can be
administered in an emergency.
3. Prefer home care when possible.
4. Allow and provide virtual contact with family and
professionals for psychological support if isolation is
recommended.
MANAGEMENT OF PATIENTS IN FOLLOW-UP
The follow-up of lung cancer patients depends on the
histological subtype (SCLC versus NSCLC) and the tumor
stage (I and II versus III versus IV). In the current SARS-CoV-2
pandemic scenario we should seek to reduce the risk of
patient contamination, promote social isolation, efficiently
detect COVID-9 cases among cancer patients, monitor the
patient’s clinical status, minimize the risk of cancer progres-
sion, guarantee timely communication with the attending
physician and the patient’s cancer care team, and provide
psychological support and reassurance (14).
The recommendations for lung cancer patients follow-up
are as follows:
1. Stage I NSCLC patients with no new symptoms: postpone
follow-up image work-up and visits.
2. Stage II and III NSCLC patients treated with curative
intent (surgery or concurrent CT and radiotherapy for
stage III disease) whose treatment was completed over
more than 1 year, without evidence of disease activity and
with no new symptoms: postpone image work-up up to 1
year. Maintain, if available, telemedicine follow-up visits
to check clinical status.
3. Stage II and III NSCLC patients treated with curative
intent (surgery), or stage III patients treated with CT and
radiotherapy, whose treatment was completed in less than
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1 year, with no new symptoms: postpone follow-up image
work-up and visits up to 6 months.
4. Stage II and III NSCLC patients treated with palliative
intent, with no new symptoms: postpone follow-up image
work-up and visits up to 6 months. Maintain, if available,
telemedicine follow-up visits every 3 months to check
clinical status.
5. Stage I to III SCLC patients treated with curative intent,
whose treatment was completed in less than 2 years,
without evidence of disease activity at last follow-up (if
less than 6 months) and with no new symptoms: postpone
follow-up image work-up and visits up to 6 months.
Maintain, if available, telemedicine follow-up visits every
3 months to check clinical status.
6. Stage I to III SCLC patients treated with curative intent,
whose treatment was completed over more than 2 years,
without evidence of disease activity at last follow-up
(if less than 6 months) and with no new symptoms:
postpone follow-up image work-up and visits up to
1 year. Maintain, if available, telemedicine follow-up visits
every 6 months to check clinical status.
7. Previously treated stage IV NSCLC or SCLC, but not
receiving active treatment currently, with no new symp-
toms: postpone follow-up image work-up and visits up to
3 months. Limit image work-up (i.e. prefer PET-TC scan
over CAT scans and bone scintigraphy). Repeat brain MRI
only if the patient is symptomatic. Maintain, if available,
telemedicine follow-up visits every 6 weeks to check
clinical status.
8. Stage IV NSCLC or SCLC currently receiving active
treatment, with no new symptoms: postpone image work-
up up to 3–4 months. Limit image work-up (i.e. prefer PET-
TC scan over CAT scans and bone scintigraphy). Repeat
brain MRI only if the patient is symptomatic. Maintain
follow-up visits every other cycle if patient is receiving
chemotherapy. If the patient is being treated with tyrosine
kinase inhibitors or ICIs, postpone follow-up visits up to 3–
4 months. Maintain, if available, telemedicine follow-up
visits every 6 weeks to check clinical status.
9. Patients with brain metastasis: Repeat brain MRI only if
symptomatic.
FURTHER RECOMMENDATIONS
1. Preferably, patients should be contacted on the day prior
to their visit and questioned whether they, or any of their
close contacts, have had any close contact with COVID-19
confirmed patients, or developed COVID-19 associated
symptoms in the last 14 days. This questioning should be
repeated upon their arrival at the clinic.
2. If the patient has/had COVID-19 associated symptoms or
contact with COVID-19 infected individuals, their visit
should be postponed. If the symptoms are mild, they
should be tested for SARS-CoV-2 infection (PCR - nasal
swab), put into domiciliary isolation and followed up by
telemedicine for 14 days, before re-starting treatment. If
symptoms are moderate to severe, the patient should be
hospitalized.
3. Limit number of companions to one, and restrict, if
possible, access of companions to the clinic. Companions
should also be interrogated about COVID-19 associated
symptoms and whether they have had contact with a
COVID-19 confirmed case in the last 14 days.
4. Patients who tested positive for SARS-CoV-2 must remain
isolated for 14 days after the start of symptoms or after
the date of the test (if asymptomatic). Depending on the
treatment and the severity of symptoms, the treatment
re-start should be delayed by up to 4 weeks or even
changed. Preferably, a new PCR from nasal swab should
be performed before treatment re-initiation. Patients
already on course of radiotherapy should not have
treatment interrupted unless necessary. Safety precautions
must be taken.
5. All patients and companions should wear masks while in
the clinic.
6. Health care providers must use adequate PPE.
7. Intravenous catheter maintenance should be scheduled
every 12 weeks if not under use.
8. Telemedicine consultations should be preferred when
feasible. Telemedicine consultations should be avoided
in patients with worsening or new symptoms, for first
time visits, and for first follow-up visit after treatment
start.
9. Patients who develop treatment complications should
refrain from being hospitalized in Phase 2 and 3 hospitals.
10. Influenza vaccination should be encouraged, as well
pneumococcic vaccination.
11. Patients suspected to have drug-induced or immune-
related pneumonitis and concomitant COVID-19 must
not have steroid initiation postponed if deemed neces-
sary by the treating physician.
’ FINAL CONSIDERATIONS
COVID-19 is a very recently described disease. These are
general recommendations, based on actual information
available. All cases should be discussed on an individual
basis, and multidisciplinary meetings through web confer-
ences are highly recommended. As mentioned previously, all
recommendations should be adjusted according to the reality
of each service and epidemiological issues. New and revised
recommendations may arise at any time, as new data become
available.
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